Patients diagnosed with a BRAF-mutated bowel cancer in Scotland will have a new treatment available to them if the disease is found to have spread PATIENTS in Scotland with a rare but particularly deadly form of colorectal cancer will have access to a new life-extending therapy on the NHS for the first time. The Scottish Medicines Consortium has given the go ahead for Braftovi to be used in combination with cetuximab in patients whose cancer has the BRAF V600 genetic mutation. This is present in around 15 per cent of patients with early-stage colorectal cancer and 6% of those whose disease has spread, with patients in this latter category typically surviving just four to six months from diagnosis.